What type of study is this?

September 10, 2025Biomolecules and BiomedicineOpen Access

Small cell lung cancer (SCLC): At the door of targeted therapies

View Full Paper

Ask AI

Bookmark

Authors

Recent developments highlight targeted therapies like DLL3 and B7-H3 in small cell lung cancer, suggesting improved outcomes.

Long-term survivors emerged from integrating atezolizumab and durvalumab with chemotherapy for SCLC.
DLL3 and B7-H3 are promising targets, with specific therapies showing significantly improved overall survival outcomes.
Emerging targeted therapies indicate a shift towards a precision-medicine approach in treating small cell lung cancer.
Key focuses include optimizing treatment strategies, managing specific toxicities, and identifying predictive biomarkers.

Tomić et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark